Cargando…
The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/ https://www.ncbi.nlm.nih.gov/pubmed/18488075 |
_version_ | 1782155229555326976 |
---|---|
author | Jenneck, Claudia Novak, Natalija |
author_facet | Jenneck, Claudia Novak, Natalija |
author_sort | Jenneck, Claudia |
collection | PubMed |
description | Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. In addition, alefacept induces apoptosis of activated memory T cells. This paper presents an overview about the clinical studies on alefacept, its mechanism of action, and the results of the clinical trials focused on efficacy and safety of alefacept in different populations. Further on, data available on the use of alefacept in combination with other therapeutic agents are discussed. |
format | Text |
id | pubmed-2386357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-23863572008-05-16 The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis Jenneck, Claudia Novak, Natalija Ther Clin Risk Manag Review Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. In addition, alefacept induces apoptosis of activated memory T cells. This paper presents an overview about the clinical studies on alefacept, its mechanism of action, and the results of the clinical trials focused on efficacy and safety of alefacept in different populations. Further on, data available on the use of alefacept in combination with other therapeutic agents are discussed. Dove Medical Press 2007-06 2007-06 /pmc/articles/PMC2386357/ /pubmed/18488075 Text en © 2007 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Jenneck, Claudia Novak, Natalija The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis |
title | The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis |
title_full | The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis |
title_fullStr | The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis |
title_full_unstemmed | The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis |
title_short | The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis |
title_sort | safety and efficacy of alefacept in the treatment of chronic plaque psoriasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/ https://www.ncbi.nlm.nih.gov/pubmed/18488075 |
work_keys_str_mv | AT jenneckclaudia thesafetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis AT novaknatalija thesafetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis AT jenneckclaudia safetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis AT novaknatalija safetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis |